You are here

Strategies for Stopping TKIs Growing Clearer

In patients with chronic myeloid leukemia (CML), longer treatment duration is associated with an increase in the odds ratio for preserving a major molecular response (MMR) six months after discontinuing tyrosine kinase inhibitor (TKI) therapy, according to recent data from a large study. In contrast, the depth of molecular response was not a predictor of molecular relapse-free survival (MRFS).

In EURO-SKI Study (European Stop Tyrosine Kinase Inhibitor Study), one of several CML treatment-stopping studies from which new data were presented at the 2016 annual meeting of the American Society of Hematology (ASH), the odds ratio for MRFS was 1.16. Thus, “ additional year of treatment increases the odds to stay in MMR at six months by 16%...” reported François-Xavier Mahon, MD, PhD, Professor of Haematology and Oncology, Bergonié Cancer Institute, University of Bordeaux, France.